The Pharmacy Times® Migraine Resource Center is a comprehensive resource for clinical news and expert insights on treatments for migraine headaches, which can cause severe throbbing pain or a pulsing sensation.
April 16th 2024
The extension trial of atogepant demonstrated an 8.5-day improvement of monthly migraine days at weeks 13 through 16 and no new safety signals were observed.
A Managed Care Focus on Assessing the Armamentarium for Multiple Sclerosis to Better Individualize Treatment
1.5 Credits / Neurology
View More
The Value of Early Intervention With Long-Acting Injectable Antipsychotics to Improve Adherence and Treatment of Schizophrenia
1.5 Credits / Neurology, Psychiatry
View More
The Promising Role of Novel and Emerging Therapies for Amyotrophic Lateral Sclerosis: Clinical and Managed Care Insights
1.0 Credit / Neurology
View More
Understanding the Role of IVIg and SCIg for the Management of CIDP: Information the Pharmacist Needs to Know to Optimize Care, featuring a Patient Perspective
1.5 Credits / Immunology, Neurology
View More
Rare and Treatment-Resistant Epilepsy Syndromes: Identifying and Addressing the Unmet Needs of Patients and Recognizing Opportunities for Pharmacist Intervention
1.5 Credits / Neurology
View More
Strategies for the Management and Treatment of ALS: The Value of Early Diagnosis and Clinical Intervention
3.0 Credits / Neurology
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Leveraging Managed Care to Optimize Best Practices in the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
1.0 Credit / Neurology
View More
Improving Outcomes and Quality of Care in Spinal Muscular Atrophy: Updates in Treatment Advances
2.0 Credits / Neurology
View More
Navigating the Use of Targeted Therapies and Individualizing Care for Patients With Ulcerative Colitis
1.5 Credits / Gastroenterology
View More
New and Emerging Treatment Strategies for Myasthenia Gravis: The Role of the Specialty Pharmacist
1.0 Credit / Neurology
View More
Improving Treatment Access for Spinal Muscular Atrophy: How Managed Care Strategies Can Ease Clinical and Caregiver Burden
1.5 Credits / Neurology
View More
Assessing the Treatment Landscape for Multiple Sclerosis to Better Individualize Care
1.5 Credits / Neurology
View More
Advances in Pharmacotherapy for Excessive Daytime Sleepiness Due to Narcolepsy
2.0 Credits / Neurology
View More
The Role of Long-Term Care and Consultant Pharmacists in the Management of Tardive Dyskinesia
1.0 Credit / Neurology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Novel Migraine Treatment Shows Mixed Results in Phase 3 Efficacy Trial
November 16th 2022Investigational migraine drug produces significant effects on both freedom-from-pain and MBS-free endpoints at 3 hours post administration and at additional efficacy measurement timepoints of 4, 6, 12, 24 and 48 hours.
Read More
A Large Proportion of Medical Students Experience Migraines, Choose to Self-Manage Symptoms
September 1st 2022Though around 42% of medical students in study experience headaches, many of these causing significant functional disability, most choose to self-manage symptoms with sleep and medication.
Read More
Study to Evaluate Efficacy of Telehealth Cognitive Behavioral Therapy for Migraine
August 11th 2022Study will analyze whether cognitive behavioral therapy telehealth can lower headache days and disability as effectively as cognitive behavioral therapy plus a preventive medication for migraine.
Read More
Survey Finds Strong Link Between Migraine Symptoms and Mental Health
August 10th 2022Survey finds that 91% of health care providers and 67% of people with migraines feel that individuals who are able to successfully manage stress and mental health conditions can also better manage the symptoms of migraine.
Read More
Abortion Ban Could Be Life-Threatening for Women With Neurological Conditions
July 28th 2022Researchers highlight how a lack of access to medications used to treat multiple sclerosis, migraines, and epilepsy, but not proven safe for pregnancy, threatens child-bearing aged women who live with these conditions.
Read More
Vyepti Shows Positive Results in the Treatment of Migraine
June 28th 2022Investigators studied the efficacy and safety of eptinezumab-jjmr in the 100 mg and 300 mg intravenous infusion dosages in individuals with 2 to 4 documented unsuccessful prior preventive treatment failures for migraine in the past 10 years.
Read More